Stock Risk Measures for Portola Pharmaceuticals Inc
A quantitative factor review, as of June 30, 2020.
- Company Info - Description, identity and sector data.
- Share Data - Stock earnings and key dates.
- Market Risk - Beta, size, liquidity and momentum measures.
- Financial Risk - Earnings and dividends.
Updated: July 01, 2020
See how we arrive at an overall risk score of
for PTLA below.
PTLA Risk Report
Our quantitative data points are meant to provide a high-level understanding of
factors in equity risk models for Portola Pharmaceuticals Inc. Portfolio managers use these
models to forecast risk, optimize portfolios and review performance.
We show how PTLA stock compares to 2,000+ US-based stocks, and to
peers in the Health Technology sector and Pharmaceuticals: Other industry.
Please do not consider this data as investment advice. Data is downloaded from
sources we deem reliable, but errors may occur.
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.
- Symbol: PTLA
- FactorPad FPID: f79rpx
- SEC CIK: 0001269021
- Share Class FIGI: BBG001SRL0Q5
- Location: South San Francisco, CA US
- Web: http://www.portola.com
- Employees: 408
Sector and Industry
- Sector: Health Technology
- Industry: Pharmaceuticals: Other
- SIC Code: 2834
Shares and Float
- Shares Outstanding: 78,483,600
- Shares Trading: 77,373,214
- Percent Trading: 98.6 %
Earnings and Dividends
- Trailing 12-month earnings: -3.77
- Next earnings date: 2020-08-11
- Dividends in last 12 months: None
- Ex-dividend date: None
Market Risk Measures
Many of the following risk metrics are standardized and transformed into
quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest
rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs
in the market. (↑↑)
Beta: 1.17 |
Stocks with higher market capitalization often have lower risk. (↑↓)
Market Capitalization: $1,411,919,964 |
Higher average daily dollar volume over the past 30 days implies lower
liquidity risk. (↑↓)
Daily Dollar Volume: $42,516,569 |
Higher price momentum stocks, aka recent winners, equate to lower risk for many
Stock Price Change (1-Year): -32.62% |
Financial Risk Measures
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Earnings Yield (E/P): -20.96% |
Companies with higher dividend yields, if sustaintable, are perceived to
have lower risk. (↑↓)
Dividend Yield (D/P): 0% |
PTLA stock risk
PORTOLA PHARMACEUTICALS INC stock beta
PTLA risk report
PTLA risk analysis
PORTOLA PHARMACEUTICALS INC credit risk
PTLA liquidity risk
PTLA systematic risk
PTLA specific risk
PORTOLA PHARMACEUTICALS INC volatility
PTLA financial ratio